(Las Vegas, Nevada, United States)  As per DelveInsight’s assessment, globally, Extensive-Stage Small Cell Lung Cancer pipeline constitutes 40+ key companies continuously working towards developing 40+ Extensive-Stage Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. 

 

“Extensive-Stage Small Cell Lung Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Extensive-Stage Small Cell Lung Cancer Market.

 

The Extensive-Stage Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Extensive-Stage Small Cell Lung Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Extensive-Stage Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years. 
• Extensive-Stage Small Cell Lung Cancer companies working in the treatment market are Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, BioNTech, Imago BioSciences, Akeso, Qilu Pharmaceutical, Amgen, Sorrento Therapeutics, BeiGene, Shanghai Henlius Biotech, Hoffmann-La Roche, Haihe Biopharma, Bristol-Myers Squibb, Xencor, and others, are developing therapies for the Extensive-Stage Small Cell Lung Cancer treatment 
• Emerging Extensive-Stage Small Cell Lung Cancer therapies in the different phases of clinical trials are- RP12146, SYHA1807, BNT411, Bomedemstat, AK104, QL1706, Tarlatamab, Socazolimab, Tislelizumab, Serplulimab, Tiragolumab, AL3810, BMS-986012, XmAb18087, and others are expected to have a significant impact on the Extensive-Stage Small Cell Lung Cancer market in the coming years.   
• In April 2022, The National Medical Products Administration (NMPA) has approved the HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) that Shanghai Henlius Biotech independently developed, for use in combination with chemotherapy as the first-line therapy for extensive-stage small cell lung cancer (ES-SCLC). Additionally, Henlius intended to submit MAA in the EU in 2022. The FDA approved HANSIZHUANG as an orphan drug in April 2022 for the treatment of SCLC, advancing HANSIZHUANG’s ongoing research and development.
• In March 2022, Akesobio entered into a collaboration agreement with Shenzhen Chipscreen Biosciences to conduct a Phase Ib/II clinical study of combination therapy of Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) and Chiauranib (a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor) in patients with ES-SCLC which progressed on combination therapy of platinum-based chemotherapy and PD-(L) 1 inhibitor as first-line treatment.
• In October 2021, The investigational anti-PD-L1 mAb adebrelimab (SHR-1316) in combination with etoposide and carboplatin (EC) compared with placebo in combination with EC met the primary endpoint of overall survival (OS) as first-line treatment for extensive-stage small cell lung cancer, according to positive results of a Phase III study published by Jiangsu Hengrui Pharmaceuticals. Based on the encouraging results, Hengrui requested a pre-New Drug Application meeting with the China National Medical Products Administration.
• BNT411 is being tested by BioNTech as a monotherapy in patients with solid tumors and in patients with advanced-stage small cell lung cancer who have never had chemotherapy in combination with atezolizumab, carboplatin, and etoposide.  At all doses studied as a monotherapy and in combination with atezolizumab, carboplatin, and etoposide in July 2021, BNT411 showed an acceptable safety profile.
• In March 2021, The Phase III, multicenter, randomized, double-blinded, parallel-group clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) combined with chemotherapy as the first-line treatment for extensive-stage small-cell lung cancer has been approved by China’s National Medical Products Administration.

 

Extensive-Stage Small Cell Lung Cancer Overview

When small cell lung cancer has progressed to more than one side of the chest, it is said to be in the extensive stage. An aggressive type of lung cancer is small cell lung cancer (SCLC). It is characterized by the fast, unchecked proliferation of certain lung cells.The cancer eventually develops a tumour and has the potential to metastasis (spread to other parts of the body)

 

Get a Free Sample PDF Report to know more about Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight

 

Emerging Extensive-Stage Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

• RP12146: Rhizen Pharmaceuticals
• SYHA1807: CSPC ZhongQi Pharmaceutical Technology
• BNT411: BioNTech
• Bomedemstat: Imago BioSciences
• AK104: Akeso
• QL1706: Qilu Pharmaceutical Co
• Tarlatamab: Amgen
• Socazolimab: Sorrento Therapeutics
• Tislelizumab: BeiGene
• Serplulimab: Shanghai Henlius Biotech  
• Tiragolumab: Hoffmann-La Roche
• AL3810: Haihe Biopharma
• BMS-986012: Bristol-Myers Squibb
• XmAb18087: Xencor

 

Extensive-Stage Small Cell Lung Cancer Route of Administration

Extensive-Stage Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

 

Extensive-Stage Small Cell Lung Cancer Molecule Type

Extensive-Stage Small Cell Lung Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

 

Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutics Assessment

• Extensive-Stage Small Cell Lung Cancer Assessment by Product Type
• Extensive-Stage Small Cell Lung Cancer By Stage and Product Type
• Extensive-Stage Small Cell Lung Cancer Assessment by Route of Administration
• Extensive-Stage Small Cell Lung Cancer By Stage and Route of Administration
• Extensive-Stage Small Cell Lung Cancer Assessment by Molecule Type
• Extensive-Stage Small Cell Lung Cancer by Stage and Molecule Type

 

DelveInsight’s Extensive-Stage Small Cell Lung Cancer Report covers around 40+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further Extensive-Stage Small Cell Lung Cancer product details are provided in the report. Download the Extensive-Stage Small Cell Lung Cancer pipeline report to learn more about the emerging Extensive-Stage Small Cell Lung Cancer therapies

 

Some of the key companies in the Extensive-Stage Small Cell Lung Cancer Therapeutics Market include:

Key companies developing therapies for Extensive-Stage Small Cell Lung Cancer are – Novartis, Amgen, Shanghai Junshi Bioscience, Eli Lilly and company, AstraZeneca, Innovent Biologics,  Kartos Therapeutics, Imago BioSciences, Aeglea Biotherapeutics, Daiichi Sankyo, BeiGene, Jiangsu HengRui Medicine,  Merck Sharp & Dohme, Qilu Pharmaceutical, Genentech, Bristol-Myers Squibb, Henilus Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd., Celgene, Xcovery Holding Company, LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, Akeso Biopharma, Rhizen Pharmaceuticals, Impact Therapeutics, Luye Pharma, Pfizer, Genprex and others.

 

Extensive-Stage Small Cell Lung Cancer Pipeline Analysis:

The Extensive-Stage Small Cell Lung Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Extensive-Stage Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Extensive-Stage Small Cell Lung Cancer Treatment.
• Extensive-Stage Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Extensive-Stage Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Extensive-Stage Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Extensive-Stage Small Cell Lung Cancer drugs and therapies

 

Extensive-Stage Small Cell Lung Cancer Pipeline Market Drivers

• The rise in incidence rate of Extensive-Stage Small Cell Lung Cancer (ESCLC), increasing Research and development are some of the important factors that are fueling the Extensive-Stage Small Cell Lung CancerMarket.

 

Extensive-Stage Small Cell Lung Cancer Pipeline Market Barriers

• However, high cost of the treatment, lack of awareness among the people for early detection of cancer and other factors are creating obstacles in the Extensive-Stage Small Cell Lung Cancer Market growth.

 

Scope of Extensive-Stage Small Cell Lung Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Extensive-Stage Small Cell Lung Cancer Companies: Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, BioNTech, Imago BioSciences, Akeso, Qilu Pharmaceutical, Amgen, Sorrento Therapeutics, BeiGene, Shanghai Henlius Biotech, Hoffmann-La Roche, Haihe Biopharma, Bristol-Myers Squibb, Xencor, and others
• Key Extensive-Stage Small Cell Lung Cancer Therapies: RP12146, SYHA1807, BNT411, Bomedemstat, AK104, QL1706, Tarlatamab, Socazolimab, Tislelizumab, Serplulimab, Tiragolumab, AL3810, BMS-986012, XmAb18087, and others
• Extensive-Stage Small Cell Lung Cancer Therapeutic Assessment: Extensive-Stage Small Cell Lung Cancer current marketed and Extensive-Stage Small Cell Lung Cancer emerging therapies
• Extensive-Stage Small Cell Lung Cancer Market Dynamics: Extensive-Stage Small Cell Lung Cancer market drivers and Extensive-Stage Small Cell Lung Cancer market barriers 

 

Request for Sample PDF Report for Extensive-Stage Small Cell Lung Cancer Pipeline Assessment and clinical trials

 

Table of Contents 

1. Extensive-Stage Small Cell Lung Cancer Report Introduction

2. Extensive-Stage Small Cell Lung Cancer Executive Summary

3. Extensive-Stage Small Cell Lung Cancer Overview

4. Extensive-Stage Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment

5. Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutics

6. Extensive-Stage Small Cell Lung Cancer Late Stage Products (Phase II/III)

7. Extensive-Stage Small Cell Lung Cancer Mid Stage Products (Phase II)

8. Extensive-Stage Small Cell Lung Cancer Early Stage Products (Phase I)

9. Extensive-Stage Small Cell Lung Cancer Preclinical Stage Products

10. Extensive-Stage Small Cell Lung Cancer Therapeutics Assessment

11. Extensive-Stage Small Cell Lung Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Extensive-Stage Small Cell Lung Cancer Key Companies

14. Extensive-Stage Small Cell Lung Cancer Key Products

15. Extensive-Stage Small Cell Lung Cancer Unmet Needs

16 . Extensive-Stage Small Cell Lung Cancer Market Drivers and Barriers

17. Extensive-Stage Small Cell Lung Cancer Future Perspectives and Conclusion

18. Extensive-Stage Small Cell Lung Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/choroidal-neovascularization-market